Andere Sprachen Revance Therapeutics, Inc.

Aktien

A1XD3D

US7613301099

RVNC

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 24.04.2024			% 5 Tage	% 1. Jan.
3,57 ^USD	-2,46 %		-5,05 %	-59,39 %

12.04.	Revance Therapeutics, Inc. präsentiert neue DAXXIFY-Daten auf der Jahrestagung der American Academy of Neurology 2024	CI
12.03.	Transcript : Revance Therapeutics, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 09:30 AM

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Revance to Present New DAXXIFY Data at the American Academy of Neurology 2024 Annual Meeting	15.04.
Northern District Of California Grants Motion To Dismiss Putative Class Action Against Biotech Company And Executives	15.04.
Revance to Present New DAXXIFY® Data at the American Academy of Neurology 2024 Annual Meeting	12.04.
Revance Therapeutics, Inc. to Present New DAXXIFY Data at the American Academy of Neurology 2024 Annual Meeting	12.04.
Revance Reports Inducement Grants under Nasdaq Listing Rule 5635(4)	28.03.
Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	27.03.
North American Morning Briefing: Stock Futures Fall With Investor Focus on Inflation Data	11.03.
Court Finds Access To Botox Trade Secrets And Similarity Of Competitor Product Supported Inference Of Trade Secrets Misappropriation	07.03.
Revance Therapeutics Prices $100 Million Public Offering	04.03.
Revance Announces Pricing of $100.0 Million Public Offering of Common Stock	04.03.
Revance Announces Proposed Public Offering of Common Stock	04.03.
Earnings Flash (RVNC) REVANCE THERAPEUTICS Posts Q4 Revenue $69.8M	28.02.
Revance Reports Fourth Quarter and Full Year 2023 Financial Results, Provides Corporate Update	28.02.
Revance Therapeutics, Inc. Provides Revenue Guidance for the Year 2024	28.02.
Revance Therapeutics, Inc. Announces Executive Changes	28.02.
Revance Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	28.02.
Revance to Release Fourth Quarter and Full Year 2023 Financial Results on Wednesday February 28, 2024	21.02.
Revance to Participate in Upcoming Investor Conferences	21.02.
Revance Therapeutics Gets Permanent J-Code for Daxxify	02.02.
Revance Receives Permanent J-Code for DAXXIFY® and Announces Publication of DAXXIFY Pivotal Study (ASPEN-1) Results in Neurology®	02.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Revance Therapeutics, Inc.

Aktien

A1XD3D

US7613301099

RVNC

Andere Sprachen

Filter